(J Am Heart Assoc. 2016;5:e003019 doi: [10.1161/JAHA.115.003019](10.1161/JAHA.115.003019))

Introduction {#jah31650-sec-0004}
============

Anemia is common in patients presenting with acute stroke. Hospital‐based studies have reported prevalence up to ≈30%.[1](#jah31650-bib-0001){ref-type="ref"}, [2](#jah31650-bib-0002){ref-type="ref"} Although anemia has been independently associated with increased mortality in a variety of conditions including chronic kidney disease,[3](#jah31650-bib-0003){ref-type="ref"} heart failure,[4](#jah31650-bib-0004){ref-type="ref"} and acute coronary syndromes,[5](#jah31650-bib-0005){ref-type="ref"} observational studies investigating the association between anemia and mortality in stroke have shown conflicting results. Early studies found no association between anemia and stroke outcomes[6](#jah31650-bib-0006){ref-type="ref"}, [7](#jah31650-bib-0007){ref-type="ref"}; however, others have found both low and high hemoglobin levels to be associated with increased mortality,[8](#jah31650-bib-0008){ref-type="ref"}, [9](#jah31650-bib-0009){ref-type="ref"}, [10](#jah31650-bib-0010){ref-type="ref"} suggesting a U‐shaped relationship. Guidelines have been unable to specify the optimal treatment options for acute stroke patients with anemia.[11](#jah31650-bib-0011){ref-type="ref"}

Previous studies were limited by small sample sizes, and a majority did not report outcomes by stroke subtype. In addition, no previous study stratified analysis by sex‐specific hemoglobin levels. This is particularly important because of the natural variance in the normal hemoglobin ranges between sexes. The literature describes various plausible mechanisms that explain how anemia could directly contribute to poor outcomes.[12](#jah31650-bib-0012){ref-type="ref"} There is a paucity of information, however, investigating the impact of an important clinical factor: whether stroke patients with anemia receive fewer preventative medications pertinent to stroke, such as antiplatelets and anticoagulants (antithrombotics). In addition, there is a lack of data regarding the comorbidity burden in anemic stroke patients and inadequate control for this in statistical analyses.

The current study aimed to clarify these important questions by assessing the impact of admission hemoglobin levels and anemia on stroke mortality at different time points up to 1‐year follow‐up. A systematic review and meta‐analysis were also carried out to further quantify the impact of admission hemoglobin and anemia on stroke mortality outcomes.

Methods {#jah31650-sec-0005}
=======

Database Study {#jah31650-sec-0006}
--------------

The study population consisted of 8013 patients with acute stroke who were admitted consecutively between January 2003 and May 2015 to Norfolk and Norwich University Hospital, a regional tertiary center in East Anglia, UK, with a catchment population of ≈750 000. Ethics approval was obtained from the Newcastle and Tyneside National Health Service Research Ethics Committee (12/NE/0170), and the study protocol was approved by the steering committee of the register used. Individual patients were not required to provide written informed consent because this source is a research database register that included all consecutive patients.

The data collection methods for this prospective hospital‐based register have been reported previously.[13](#jah31650-bib-0013){ref-type="ref"} Briefly, the data were obtained from paper and electronic records, reviewed, and then entered into the register database. This was done by the hospital stroke data team and vetted by clinical team members for accuracy. For each patient admitted, the prestroke modified Rankin Scale score (scores are defined in Table [1](#jah31650-tbl-0001){ref-type="table-wrap"}), as modified by UK‐TIA investigators,[14](#jah31650-bib-0014){ref-type="ref"} was ascertained from nursing and medical records by stroke specialist nurses. At discharge, deceased or living status was recorded to capture in‐hospital mortality. Follow‐up for mortality was obtained by electronic record linkage with the Office of National Statistics data through hospital episodes in May 2015. For the purposes of this study, the follow‐up was truncated at 365 days for all patients.

###### 

Sex‐Specific Sample Characteristics by Anemia Status

                                                                        Male          Female                                             
  --------------------------------------------------------------------- ------------- ------------- --------- ------------ ------------- ---------
  Number                                                                1017 (26.7)   2794 (73.3)             947 (22.5)   3255 (77.5)   
  Age, y                                                                                            \<0.001                              \<0.001
  ≤60                                                                   46 (4.5)      424 (15.2)              29 (3.1)     208 (6.4)     
  61--65                                                                32 (3.1)      282 (10.1)              21 (2.2)     143 (4.4)     
  66--70                                                                50 (4.9)      340 (12.2)              33 (3.5)     231 (7.1)     
  71--75                                                                127 (12.5)    411 (14.7)              65 (6.9)     344 (10.6)    
  76--80                                                                187 (18.4)    470 (16.8)              137 (14.5)   522 (16.0)    
  81--85                                                                247 (24.3)    475 (17.0)              232 (24.5)   747 (22.9)    
  86--90                                                                234 (23.0)    279 (10.0)              253 (26.7)   635 (19.2)    
  ≥91                                                                   94 (9.2)      113 (4.0)               177 (18.7)   435 (13.4)    
  Prestroke comorbidity                                                                                                                  
  Coronary heart disease                                                304 (29.9)    446 (16.0)    \<0.001   230 (24.3)   475 (14.6)    \<0.001
  Previous stroke                                                       287 (28.2)    607 (21.7)    \<0.001   261 (27.6)   763 (23.4)    0.009
  Congestive heart failure                                              143 (14.1)    154 (5.5)     \<0.001   147 (15.5)   255 (7.8)     \<0.001
  Atrial fibrillation                                                   217 (21.3)    307 (11.0)    \<0.001   206 (21.8)   508 (15.6)    \<0.001
  Hypertension                                                          422 (41.5)    650 (23.3)    \<0.001   393 (41.5)   1044 (32.1)   \<0.001
  Hyperlipidemia                                                        76 (7.5)      99 (3.5)      \<0.001   42 (4.4)     135 (4.1)     0.698
  Diabetes mellitus                                                     183 (18.0)    231 (8.3)     \<0.001   137 (14.5)   242 (7.4)     \<0.001
  Peripheral vascular disease                                           63 (6.2)      49 (1.8)      \<0.001   28 (3.0)     61 (1.9)      0.042
  GI bleeding and peptic ulcer                                          81 (8.0)      118 (4.2)     \<0.001   62 (6.5)     142 (4.4)     0.006
  COPD                                                                  90 (8.8)      113 (4.0)     \<0.001   65 (6.9)     107 (3.3)     \<0.001
  Chronic kidney disease                                                93 (9.1)      37 (1.3)      \<0.001   50 (5.3)     69 (2.1)      \<0.001
  Falls                                                                 161 (15.8)    160 (5.7)     \<0.001   275 (29.0)   557 (17.1)    \<0.001
  Malignancy                                                            240 (23.6)    274 (9.8)     \<0.001   112 (11.8)   278 (8.5)     0.002
  Dementia                                                              47 (4.6)      43 (1.5)      \<0.001   75 (7.9)     121 (3.7)     \<0.001
  Prior antithrombotic use                                                                          \<0.001                              0.286
  No                                                                    447 (44.0)    1538 (55.0)             499 (52.7)   1779 (54.7)   
  Yes                                                                   570 (56.0)    1256 (45.0)             448 (47.3)   1476 (45.3)   
  Prestroke Rankin Scale score[a](#jah31650-note-0002){ref-type="fn"}                               \<0.001                              \<0.001
  0                                                                     556 (54.7)    2119 (75.8)             388 (41.0)   1955 (60.1)   
  1                                                                     155 (15.2)    286 (10.2)              135 (14.3)   399 (12.3)    
  2                                                                     96 (9.4)      147 (5.3)               121 (12.8)   303 (9.3)     
  3                                                                     131 (12.9)    142 (5.1)               160 (16.9)   354 (10.9)    
  4                                                                     54 (5.3)      73 (2.6)                90 (9.5)     176 (5.4)     
  5                                                                     25 (2.5)      27 (1.0)                53 (5.6)     68 (2.1)      
  Stroke type                                                                                       0.088                                0.002
  Hemorrhagic                                                           121 (11.9)    392 (14.0)              95 (10.0)    454 (13.9)    
  Ischemic                                                              896 (88.1)    2402 (86.0)             852 (90.0)   2801 (86.1)   
  OCSP classification                                                                               0.002                                \<0.001
  TACS                                                                  215 (21.1)    500 (17.9)              248 (26.2)   699 (21.5)    
  PACS                                                                  359 (35.3)    900 (32.2)              312 (32.9)   1084 (33.3)   
  POCS                                                                  169 (16.6)    548 (19.6)              118 (12.5)   521 (16.0)    
  LACS                                                                  209 (20.6)    696 (24.9)              186 (19.6)   786 (24.1)    
  Undefined                                                             65 (6.4)      150 (5.4)               83 (8.8)     165 (5.1)     
  Inpatient mortality                                                                               \<0.001                              \<0.001
  Living                                                                731 (71.9)    2393 (85.6)             635 (67.1)   2546 (78.2)   
  Deceased                                                              286 (28.1)    401 (14.4)              709 (21.8)   312 (22.5)    

The data are presented as number (%) for categorical variables. COPD indicates chronic obstructive pulmonary disease; GI, gastrointestinal; LACS, lacunar stroke; OCSP, Oxfordshire Community Stroke Project; PACS, partial anterior circulation stroke; POCS, posterior circulation stroke; TACS, total anterior circulation stroke.

0: no symptoms; 1: no significant disability despite symptoms, able to carry out all usual duties and activities; 2: slight disability, unable to perform all previous activities but able to look after own affairs without assistance; 3: moderate disability, requires some help but able to walk without assistance; 4: moderately severe disability, unable to walk without assistance and to attend to own bodily needs without assistance; 5: severe disability---bedridden, incontinent, and requiring constant nursing care and attention.

The variables included were age, sex, stroke subtype (ischemic or hemorrhagic), prestroke disability depicted by modified Rankin Scale score (0--5), Oxfordshire Community Stroke Project (OCSP) classification (total anterior circulation stroke, partial anterior circulation stroke, posterior circulation stroke, lacunar stroke), hemoglobin levels at admission, comorbidities (coronary heart disease, congestive heart failure, atrial fibrillation, hypertension, hyperlipidemia, previous stroke, diabetes mellitus, peripheral vascular disease, gastrointestinal bleeding, peptic ulcers, chronic obstructive pulmonary disease, chronic kidney disease, falls, malignancy, dementia), and prior use of antithrombotics. Mortality was assessed at several different time points: inpatient; at 7 and 14 days; at 1, 3, and 6 months; and at 1 year. Results were displayed selectively in Tables [2](#jah31650-tbl-0002){ref-type="table-wrap"} and [3](#jah31650-tbl-0003){ref-type="table-wrap"}, and data for the 7‐ and 14‐day time points were not included because of the similarity in results and to ensure brevity. Only confirmed cases of stroke were included. Stroke was diagnosed using evidence from clinical features and neuroimaging (typically computed tomography and, in some cases, magnetic resonance imaging). Anemia was defined according to the World Health Organization criteria of hemoglobin \<12.0 g/dL in women and \<13.0 g/dL in men, and elevated hemoglobin was defined as \>15.5 g/dL in women and \>17.0 g/dL in men.[15](#jah31650-bib-0015){ref-type="ref"}

###### 

The Impact of Hemoglobin Levels on Mortality at Different Time Points (Logistic Regression)

  Variable             Hemoglobin quintile   Events                                                             
  -------------------- --------------------- ------------------- ------ ------------------- ------------------- ------
  Male ischemic                                                                                                 
  Number               635                   675                 667    644                 677                 
  Inpatient            2.64 (1.83--3.81)     1.56 (1.08--2.25)   1.00   1.59 (1.06--2.38)   1.62 (1.08--2.42)   511
  1 month              2.99 (2.06--4.34)     1.74 (1.19--2.53)   1.00   1.55 (1.03--2.34)   1.79 (1.19--2.68)   488
  3 months             3.09 (2.24--4.25)     1.34 (0.96--1.85)   1.00   1.18 (0.82--1.69)   1.37 (0.96--1.95)   674
  6 months             2.92 (2.16--3.94)     1.37 (1.01--1.85)   1.00   1.05 (0.75--1.46)   1.16 (0.83--1.63)   796
  1 year               2.90 (2.18--3.86)     1.43 (1.08--1.90)   1.00   1.17 (0.86--1.59)   1.17 (0.86--1.60)   971
  Male hemorrhagic                                                                                              
  Number               83                    109                 103    87                  131                 
  Inpatient            1.23 (0.58--2.60)     0.83 (0.42--1.65)   1.00   0.86 (0.39--1.86)   1.05 (0.53--2.09)   176
  1 month              1.22 (0.59--2.51)     0.92 (0.48--1.78)   1.00   0.81 (0.39--1.70)   0.93 (0.48--1.80)   173
  3 months             1.16 (0.55--2.42)     0.67 (0.34--1.30)   1.00   0.76 (0.38--1.57)   0.68 (0.35--1.57)   200
  6 months             1.65 (0.77--3.55)     0.81 (0.41--1.60)   1.00   0.78 (0.38--1.62)   0.73 (0.38--1.41)   221
  1 year               1.97 (0.92--4.22)     0.81 (0.42--1.58)   1.00   0.73 (0.35--1.51)   0.79 (0.41--1.51)   229
  Female ischemic                                                                                               
  Number               698                   748                 700    752                 755                 
  Inpatient            1.47 (1.08--1.98)     1.05 (0.77--1.43)   1.00   1.39 (1.01--1.90)   1.20 (0.88--1.63)   792
  1 month              1.48 (1.09--2.01)     1.16 (0.85--1.58)   1.00   1.23 (0.89--1.69)   1.26 (0.92--1.73)   733
  3 months             1.70 (1.28--2.25)     1.16 (0.87--1.54)   1.00   1.34 (1.00--1.79)   1.19 (0.89--1.58)   1007
  6 months             1.86 (1.42--2.44)     1.22 (0.93--1.60)   1.00   1.44 (1.09--1.89)   1.26 (0.96--1.67)   1159
  1 year               1.86 (1.44--2.41)     1.23 (0.96--1.59)   1.00   1.29 (0.99--1.68)   1.13 (0.87--1.46)   1328
  Female hemorrhagic                                                                                            
  Number               72                    100                 132    127                 118                 
  Inpatient            2.56 (1.23--5.32)     0.80 (0.41--1.57)   1.00   0.80 (0.54--1.81)   1.35 (0.74--2.47)   229
  1 month              2.61 (1.31--5.36)     0.80 (0.42--1.55)   1.00   1.12 (0.62--2.01)   1.46 (0.81--2.63)   226
  3 months             2.26 (1.10--4.64)     0.88 (0.47--1.67)   1.00   0.94 (0.53--1.68)   1.22 (0.68--2.19)   256
  6 months             2.02 (0.98--4.16)     0.97 (0.52--1.82)   1.00   0.80 (0.45--1.42)   1.22 (0.68--2.18)   278
  1 year               2.59 (1.23--5.44)     1.20 (0.64--2.25)   1.00   0.95 (0.54--1.68)   1.35 (0.75--2.41)   292

The cutoff points for the quintiles are as follows: male: 12.4, 13.8, 14.6, and 15.6 g/dL; female: 11.7, 12.8, 13.6, and 14.5 g/dL. The variables adjusted for were age, Oxford Community Stroke Project classification, prestroke Rankin Scale score, prior antithrombotic use, coronary heart disease, previous stroke, congestive heart failure, atrial fibrillation, hypertension, hyperlipidemia, diabetes mellitus, peripheral vascular disease, chronic obstructive pulmonary disease, chronic kidney disease, falls, malignancy, dementia, gastrointestinal bleeding, and peptic ulcer. We also adjusted for International Normalized Ratio in patients with hemorrhagic stroke. The International Normalized Ratio was included as a dichotomous categorical variable: \<1.40 versus ≥1.40. Data for the time points 7 and 14 days were removed for brevity. Mean ages for the male quintiles were 82.80, 80.48, 78.49, 78.09, and 78.38 years for quintiles 1--5, respectively. Mean ages for female quintiles were 83.04, 81.81, 80.45, 78.96, and 78.06 years for quintiles 1--5, respectively.

###### 

Effect of Anemia and Elevated Hemoglobin on Stroke Outcomes at Different Time Points (Logistic Regression)

                       Anemia              Normal   Elevated Hemoglobin   Events
  -------------------- ------------------- -------- --------------------- --------
  Male ischemic                                                           
  Number               896                 2277     125                   
  Inpatient            1.75 (1.37--2.25)   1.00     1.85 (1.03--3.32)     511
  1 month              1.86 (1.46--2.38)   1.00     1.79 (1.00--3.20)     488
  3 months             2.18 (1.75--2.72)   1.00     1.86 (1.08--3.18)     674
  6 months             2.25 (1.83--2.78)   1.00     1.46 (0.86--2.48)     796
  1 year               2.25 (1.84--2.74)   1.00     1.50 (0.91--2.47)     971
  Male hemorrhagic                                                        
  Number               121                 367      25                    
  Inpatient            1.33 (0.77--2.31)   1.00     3.30 (1.19--9.17)     176
  1 month              1.42 (0.83--2.42)   1.00     2.90 (1.08--7.75)     173
  3 months             1.39 (0.81--2.39)   1.00     2.08 (0.75--5.78)     200
  6 months             1.64 (0.94--2.85)   1.00     1.56 (0.56--4.40)     221
  1 year               1.76 (1.01--3.04)   1.00     1.56 (0.56--4.35)     229
  Female ischemic                                                         
  Number               852                 2585     216                   
  Inpatient            1.20 (0.97--1.49)   1.00     1.30 (0.87--1.94)     792
  1 month              1.29 (1.04--1.60)   1.00     1.49 (1.00--2.21)     733
  3 months             1.39 (1.14--1.70)   1.00     1.19 (0.81--1.75)     1007
  6 months             1.44 (1.18--1.75)   1.00     1.12 (0.78--1.62)     1159
  1 year               1.48 (1.23--1.79)   1.00     1.04 (0.73--1.48)     1328
  Female hemorrhagic                                                      
  Number               95                  418      36                    
  Inpatient            1.90 (1.09--3.33)   1.00     2.76 (1.16--6.56)     229
  1 month              1.82 (1.06--3.11)   1.00     2.11 (0.92--4.82)     226
  3 months             1.80 (1.04--3.13)   1.00     2.08 (0.91--4.77)     256
  6 months             2.05 (1.17--3.59)   1.00     2.99 (1.29--6.90)     278
  1 year               2.11 (1.19--3.74)   1.00     2.63 (1.14--6.05)     292

The cutoff points were as follows: male: 13.0 and 17.0 g/dL; female: 12.0 and 15.5 g/dL. The variables adjusted for were age, Oxford Community Stroke Project classification, prestroke Rankin Scale score, prior antithrombotic use, coronary heart disease, previous stroke, congestive heart failure, atrial fibrillation, hypertension, hyperlipidemia, diabetes mellitus, peripheral vascular disease, chronic obstructive pulmonary disease, chronic kidney disease, falls, malignancy, dementia, gastrointestinal bleeding, and peptic ulcer. We also adjusted for International Normalized Ratio in patients with hemorrhagic stroke. The International Normalized Ratio was included as a dichotomous categorical variable: \<1.40 vs ≥1.40. Data for the time points 7 and 14 days were removed for brevity.

The associations between hemoglobin levels and age, sex, prestroke modified Rankin Scale score, stroke type, OCSP classification, comorbidities, prior antithrombotic use, and inpatient mortality were assessed using the chi‐square test. Logistic regression models were constructed to assess the impact of hemoglobin levels (by quintiles) and anemia on odds of death. Univariate and multivariate models were used to calculate unadjusted and adjusted odds ratios (ORs). Sex‐ and stroke type--specific analyses were performed controlling for age, OCSP classification, prestroke modified Rankin Scale score, comorbidities, and prior antithrombotic usage.

To better understand the potential mediating factors for the observed associations, we examined the distribution of selected chronic comorbidities between patients with anemia and no anemia and assessed the differences in proportions of patients receiving antithrombotic medications by a vascular indication (defined as presence of previous stroke, coronary heart disease, diabetes mellitus, peripheral vascular disease, hypertension, and atrial fibrillation). The analysis was performed using the SPSS version 23.0 (IBM Corp).

Systematic Review and Meta‐Analysis {#jah31650-sec-0007}
-----------------------------------

We selected full journal articles reporting on studies that evaluated the association between baseline hemoglobin or anemia and subsequent mortality in patients diagnosed with stroke. PubMed and Embase were searched from inception until December 2014 using the following search terms with no language restriction: *stroke OR intracranial‐hemorrhage OR intracerebral‐hemorrhage AND haemoglobin OR hemoglobin OR anaemia OR anemia AND mortality OR fatal\* OR survival OR death NOT rivaroxaban OR dabigatran OR apixaban OR sickle OR surgery OR glycated OR glycosylated OR HbA1C or erythropoie\**. In addition, we checked the bibliographies of relevant articles for any studies that met our selection criteria.

Two reviewers (R.B. and K.H.) independently screened abstracts and titles. Potentially relevant studies were reviewed to confirm their eligibility. The selection and data extraction of included studies were performed by R.B. and K.H. and checked by a senior reviewer (Y.K.L.). To assess study validity, included studies were assessed for the methods used for diagnosing stroke, determination of hemoglobin levels and anemia, ascertainment of mortality or outcome subsequent to the stroke, and the analytic procedures aimed at minimizing the risk of bias from confounders. We pooled the reported associations (adjusted OR if available) using the inverse variance method and random‐effects model in RevMan 5.3 software (Nordic Cochrane Center). The comparisons of interest were for categories of anemia versus no anemia in patients with ischemic and hemorrhagic stroke versus the referent "normal" category. We evaluated heterogeneity by calculating the I^2^ statistic, for which a value \>50% was indicative of substantial heterogeneity. We also aimed to check for publication bias through a funnel plot if there were \>10 eligible studies in our systematic review.

Results {#jah31650-sec-0008}
=======

Database Study {#jah31650-sec-0009}
--------------

Of the 11 886 episodes recorded in the registry, 3873 were excluded for various reasons (Figure [1](#jah31650-fig-0001){ref-type="fig"}. Overall, 2659 of these episodes were excluded because of missing data, and 991 were excluded because they were related to secondary entry into the register due to subsequent stroke. The sample included in the current study consisted of 8013 patients with acute stroke admitted consecutively between January 2003 and May 2015. The mean age in the cohort was 77.81±11.83 years, 52.4% were women, and 86.7% had ischemic stroke. The most common OCSP stroke classification was partial anterior circulation stroke (33.1%), and the majority of patients (62.6%) had a prestroke modified Rankin Scale score of 0. Inpatient mortality was 21.3%, and 1 in 4 patients (24.5%) had anemia on admission.

![Patient inclusion chart. mRS indicates modified Rankin Scale score; OCSP, Oxfordshire Community Stroke Project.](JAH3-5-e003019-g001){#jah31650-fig-0001}

Table [1](#jah31650-tbl-0001){ref-type="table-wrap"} shows sex‐specific sample characteristics by anemia status. Increasing age, higher prestroke disability, increased stroke severity, inpatient mortality, and all comorbidities (with the exception of hyperlipidemia in women) were associated with anemia (Figures [2](#jah31650-fig-0002){ref-type="fig"} and [3](#jah31650-fig-0003){ref-type="fig"}). Prior antithrombotic use in men and ischemic stroke in women were also associated with anemia.

![Prevalence of comorbidities by anemia status in men. The vertical line represents the expected proportion of comorbidity based on the proportion of stroke patients with anemia. Any dark bars to the right of the vertical line represent higher comorbidity burden in anemic patients compared with patients who were not anemic. AF indicates atrial fibrillation; CHD, coronary heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease.](JAH3-5-e003019-g002){#jah31650-fig-0002}

![Prevalence of comorbidities by anemia status in women. The vertical line represents the expected proportion of comorbidity based on the proportion of stroke patients with anemia. Any dark bars to the right of the vertical line represent higher comorbidity burden in anemic patients compared with patients who were not anemic. AF indicates atrial fibrillation; CHD, coronary heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease.](JAH3-5-e003019-g003){#jah31650-fig-0003}

Table [2](#jah31650-tbl-0002){ref-type="table-wrap"} depicts the impact of hemoglobin levels on stroke mortality by quintiles of sex‐specific admission hemoglobin levels, presented separately for ischemic and hemorrhagic stroke. Quintile 1 contains those with the lowest values, and quintile 5 has the highest. The cutoff points were 12.40, 13.80, 14.64, and 15.60 g/dL for men and 11.70, 12.80, 13.60, and 14.50 g/dL for women. In men with ischemic stroke, low hemoglobin (quintile 1) was significantly associated with increased mortality at all time points measured compared with those with normal hemoglobin levels (quintile 3). High hemoglobin (quintile 5) was also associated with increased odds of mortality at 4 time points; inpatient, 7 and 14 days, and 1 month. This suggested a U‐shaped relationship between hemoglobin levels and short‐term mortality in men with ischemic stroke. In women with ischemic stroke, low hemoglobin levels were significantly associated with mortality at 5 time points; inpatient; 1, 3, and 6 months; and 1 year. In women with hemorrhagic stroke, low hemoglobin levels were associated with increased mortality at all time points.

Table [3](#jah31650-tbl-0003){ref-type="table-wrap"} shows the impact of anemia and elevated hemoglobin levels on mortality. In men with ischemic stroke, anemia was associated with higher odds of death at all time points assessed, and elevated hemoglobin was associated with increased odds of death at 3 time points; inpatient, 1 month, and 3 months. In men with hemorrhagic stroke, anemia was associated with increased mortality at 1 year, and elevated hemoglobin was associated with increased mortality at 4 time points; inpatient, 7 and 14 days, and 1 month. In women with ischemic stroke, anemia was associated with increased mortality at 1, 3, and 6 months and 1 year, whereas elevated hemoglobin was associated with increased mortality at 7 and 14 days and 1 month. In women with hemorrhagic stroke, anemia was associated with increased mortality at all time points assessed, whereas elevated hemoglobin was associated with increased mortality at 3 time points; inpatient, 6 months, and 1 year.

Table [4](#jah31650-tbl-0004){ref-type="table-wrap"} depicts prior antithrombotic use by anemia status and vascular indication. In women with a positive vascular indication, those with anemia were less likely to be on prior antithrombotics compared with those without anemia (*P*=0.032). Conversely, in men with a negative vascular indication, those with anemia were more likely to be on prior antithrombotics than those without anemia (*P*\<0.001). In addition, anemia was associated with increased comorbidity burden in both sexes (Figures [2](#jah31650-fig-0002){ref-type="fig"} and [3](#jah31650-fig-0003){ref-type="fig"}).

###### 

Use of Prior Antithrombotic by Anemia Status and Vascular Indication (Chi‐Square Test)

                      Vascular Indication Yes[a](#jah31650-note-0008){ref-type="fn"}   Vascular Indication No                                      
  ------------------- ---------------------------------------------------------------- ------------------------ ------- ------------ ------------- ---------
  Male                                                                                                          0.971                              \<0.001
  No antithrombotic   237 (34.2)                                                       456 (65.8)                       210 (16.3)   1082 (83.7)   
  Antithrombotic      447 (34.3)                                                       857 (65.7)                       123 (23.6)   399 (76.4)    
  Female                                                                                                        0.032                              0.334
  No antithrombotic   270 (28.9)                                                       665 (71.1)                       229 (17.1)   1114 (82.9)   
  Antithrombotic      350 (24.9)                                                       1057 (75.1)                      98 (19.0)    419 (81.0)    

Indications considered were previous stroke, coronary heart disease, diabetes, hypertension, peripheral vascular disease, and atrial fibrillation.

Systematic Review and Meta‐Analysis {#jah31650-sec-0010}
-----------------------------------

Our search identified 1424 citations. After detailed screening, 20 studies were included in our systematic review; the flow chart of study selection is shown in Figure [4](#jah31650-fig-0004){ref-type="fig"}, and Tables [5](#jah31650-tbl-0005){ref-type="table-wrap"} and [6](#jah31650-tbl-0006){ref-type="table-wrap"} show the key features of the selected studies. Overall, 10 studies assessed the impact of anemia on stroke[1](#jah31650-bib-0001){ref-type="ref"}, [2](#jah31650-bib-0002){ref-type="ref"}, [10](#jah31650-bib-0010){ref-type="ref"}, [16](#jah31650-bib-0016){ref-type="ref"}, [17](#jah31650-bib-0017){ref-type="ref"}, [18](#jah31650-bib-0018){ref-type="ref"}, [19](#jah31650-bib-0019){ref-type="ref"}, [20](#jah31650-bib-0020){ref-type="ref"}, [21](#jah31650-bib-0021){ref-type="ref"}, [22](#jah31650-bib-0022){ref-type="ref"} and 10 evaluated the association between stroke and hemoglobin levels.[6](#jah31650-bib-0006){ref-type="ref"}, [7](#jah31650-bib-0007){ref-type="ref"}, [8](#jah31650-bib-0008){ref-type="ref"}, [9](#jah31650-bib-0009){ref-type="ref"}, [23](#jah31650-bib-0023){ref-type="ref"}, [24](#jah31650-bib-0024){ref-type="ref"}, [25](#jah31650-bib-0025){ref-type="ref"}, [26](#jah31650-bib-0026){ref-type="ref"}, [27](#jah31650-bib-0027){ref-type="ref"}, [28](#jah31650-bib-0028){ref-type="ref"} In terms of study design, 3 were retrospective cohort studies,[1](#jah31650-bib-0001){ref-type="ref"}, [16](#jah31650-bib-0016){ref-type="ref"}, [20](#jah31650-bib-0020){ref-type="ref"} 13 were prospective cohort studies,[2](#jah31650-bib-0002){ref-type="ref"}, [6](#jah31650-bib-0006){ref-type="ref"}, [7](#jah31650-bib-0007){ref-type="ref"}, [8](#jah31650-bib-0008){ref-type="ref"}, [9](#jah31650-bib-0009){ref-type="ref"}, [10](#jah31650-bib-0010){ref-type="ref"}, [17](#jah31650-bib-0017){ref-type="ref"}, [18](#jah31650-bib-0018){ref-type="ref"}, [19](#jah31650-bib-0019){ref-type="ref"}, [22](#jah31650-bib-0022){ref-type="ref"}, [23](#jah31650-bib-0023){ref-type="ref"}, [24](#jah31650-bib-0024){ref-type="ref"}, [25](#jah31650-bib-0025){ref-type="ref"} and 2 were secondary analyses of randomized control trials.[27](#jah31650-bib-0027){ref-type="ref"}, [28](#jah31650-bib-0028){ref-type="ref"} There were also 2 studies that did not state the design.[21](#jah31650-bib-0021){ref-type="ref"}, [26](#jah31650-bib-0026){ref-type="ref"} There was a high degree of diversity in geographic location, with cohorts from Germany,[8](#jah31650-bib-0008){ref-type="ref"}, [19](#jah31650-bib-0019){ref-type="ref"}, [25](#jah31650-bib-0025){ref-type="ref"} Switzerland,[16](#jah31650-bib-0016){ref-type="ref"}, [20](#jah31650-bib-0020){ref-type="ref"} the United States,[18](#jah31650-bib-0018){ref-type="ref"}, [24](#jah31650-bib-0024){ref-type="ref"} the People\'s Republic of China,[2](#jah31650-bib-0002){ref-type="ref"}, [22](#jah31650-bib-0022){ref-type="ref"} Canada,[23](#jah31650-bib-0023){ref-type="ref"}, [28](#jah31650-bib-0028){ref-type="ref"} India,[6](#jah31650-bib-0006){ref-type="ref"} Israel,[10](#jah31650-bib-0010){ref-type="ref"} the Republic of Korea,[9](#jah31650-bib-0009){ref-type="ref"} Denmark,[21](#jah31650-bib-0021){ref-type="ref"} Taiwan,[17](#jah31650-bib-0017){ref-type="ref"} the United Kingdom,[26](#jah31650-bib-0026){ref-type="ref"} and Poland.[7](#jah31650-bib-0007){ref-type="ref"} In addition, 2 studies were conducted across multiple countries.[1](#jah31650-bib-0001){ref-type="ref"}, [27](#jah31650-bib-0027){ref-type="ref"} Regarding stroke type, 9 studies assessed patients with ischemic stroke,[1](#jah31650-bib-0001){ref-type="ref"}, [2](#jah31650-bib-0002){ref-type="ref"}, [8](#jah31650-bib-0008){ref-type="ref"}, [9](#jah31650-bib-0009){ref-type="ref"}, [17](#jah31650-bib-0017){ref-type="ref"}, [20](#jah31650-bib-0020){ref-type="ref"}, [21](#jah31650-bib-0021){ref-type="ref"}, [27](#jah31650-bib-0027){ref-type="ref"}, [28](#jah31650-bib-0028){ref-type="ref"} 6 assessed patients with hemorrhagic stroke,[9](#jah31650-bib-0009){ref-type="ref"}, [18](#jah31650-bib-0018){ref-type="ref"}, [22](#jah31650-bib-0022){ref-type="ref"}, [23](#jah31650-bib-0023){ref-type="ref"}, [24](#jah31650-bib-0024){ref-type="ref"}, [25](#jah31650-bib-0025){ref-type="ref"} and 5 evaluated both types of stroke.[6](#jah31650-bib-0006){ref-type="ref"}, [7](#jah31650-bib-0007){ref-type="ref"}, [10](#jah31650-bib-0010){ref-type="ref"}, [16](#jah31650-bib-0016){ref-type="ref"}, [26](#jah31650-bib-0026){ref-type="ref"} The number of participants in the studies ranged from 106 to 3020. When combined with the participants from the current study, the total pooled study population included 29 943 participants of whom 24 816 were meta‐analyzed. ORs included in the meta‐analysis were from the mortality time point of 1 year or the closest time point available to 1 year.

![Flow diagram of study selection.](JAH3-5-e003019-g004){#jah31650-fig-0004}

###### 

Characteristics of Studies Examining the Relationship Between Anemia and Hemoglobin Levels and Stroke Outcomes

  Author                                                     Years Sampled   Study Design               n      Exposure                                                                Outcomes                                                                  Main Result
  ---------------------------------------------------------- --------------- -------------------------- ------ ----------------------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  Bhatia et al[6](#jah31650-bib-0006){ref-type="ref"}        2000--2001      Prospective                116    Admission Hb                                                            Mortality at 30 days                                                      Hb not associated with outcome
  Bussiere et al[23](#jah31650-bib-0023){ref-type="ref"}     2003--2008      Prospective                2406   Admission Hb divided into quintiles---cutoffs: 100, 120, 140, 160 g/L   Mortality at 1 year, mRS at discharge                                     Hb predicted mortality at 1 year (aOR 1.39, 95% CI 1.01--1.91) in Hb \<100 vs 141--160 g/L
  Chang et al[24](#jah31650-bib-0024){ref-type="ref"}        2008--2010      Prospective                106    Admission Hb, nadir Hb, and transfusion                                 In‐hospital mortality, length of stay, and disability at discharge        Admission anemia did not predict outcomes
  Czlonkowska et al[7](#jah31650-bib-0007){ref-type="ref"}   1991--1992      Prospective                345    Admission Hb                                                            Mortality at 30 days                                                      Hb not associated with outcome
  Diedler et al[25](#jah31650-bib-0025){ref-type="ref"}      2004--2006      Prospective                196    Admission, mean and nadir Hb                                            mRS at discharge and 6 months                                             Admission Hb did not predict outcomes
  Del Fabbro et al[16](#jah31650-bib-0016){ref-type="ref"}   2001--2003      Retrospective              890    Anemia at admission                                                     In‐hospital mortality, survival at 1 year                                 Higher Hb predicted decreased mortality at 1 year: HR 0.98 (95% CI 0.97--1.00)
  Gray et al[26](#jah31650-bib-0026){ref-type="ref"}         1985--1986      ---                        122    Admission Hb                                                            Mortality at 4 and 12 weeks                                               Hb not associated with outcome
  Hao et al[2](#jah31650-bib-0002){ref-type="ref"}           2002--2008      Prospective                1176   Anemia at admission                                                     In‐patient mortality, mortality, and disability (mRS \>2) at 12 months    Anemia associated with inpatient mortality (aOR 1.66, 95% CI 1.08--2.56) and mortality at 12 months (aOR 1.56, 95% CI 1.05--2.31)
  Huang et al[17](#jah31650-bib-0017){ref-type="ref"}        2001--2003      Prospective                774    Anemia at admission                                                     Inpatient mortality, mRS at discharge, stroke recurrence at 3 years       Anemia was associated with increased mortality at 3 years (aOR 2.22, 95% CI 1.13--4.39)
  Kellert et al[8](#jah31650-bib-0008){ref-type="ref"}       1998--2009      Prospective                217    Admission, mean and nadir Hb                                            Mortality and mRS at 3 months                                             Hb decrease was associated with increased mortality at 3 months (OR 1.34: 1.01--1.76) but admission Hb was not (OR not given)
  Kumar et al[18](#jah31650-bib-0018){ref-type="ref"}        1999--2005      Prospective                685    Anemia at admission                                                     Mortality at 30 days, ICH volume                                          Anemia is not a predictor of mortality on multivariable analysis (OR 1.5, 95% CI 0.9--2.4)
  Kuramatsu et al[19](#jah31650-bib-0019){ref-type="ref"}    2006--2010      Prospective                435    Anemia at admission                                                     mRS at 90 days and 1 year                                                 Anemia was associated with poor long‐term outcome (mRS 4--6 at 1 year; OR 7.5)
  Milionis et al[20](#jah31650-bib-0020){ref-type="ref"}     2003--2011      Retrospective              2439   Anemia at admission                                                     Mortality and disability at 12 months                                     Anemia associated with mortality at 12 months (OR 2.70, 95% CI 2.12--3.43)
  Nybo et al[21](#jah31650-bib-0021){ref-type="ref"}         2003--2004      ---                        250    Anemia at admission                                                     Mortality at 6 months                                                     Anemia associated with greater risk of death at 6 months (OR 4.7, 95% CI 1.1--8.2)
  Park et al[9](#jah31650-bib-0009){ref-type="ref"}          2004--2009      Prospective                2681   Admission, nadir, time‐averaged, and discharge Hb                       Mortality and mRS at 3 months                                             Admission Hb predicted mortality 3 months (aOR: Q1 vs Q3 was 3.74 \[95% CI 2.03--6.89\] and Q5 vs Q3 was 1.99 \[95% CI 1.02--3.91\])
  Sharma et al[27](#jah31650-bib-0027){ref-type="ref"}       2003--2011      Post hoc analysis of RCT   3020   Admission Hb and Hb \<13 g/dL                                           All‐cause mortality                                                       Hb \<13 g/dL was a significant predictor of mortality (HR 1.60, 95% CI 1.22--2.10)
  Sico et al[1](#jah31650-bib-0001){ref-type="ref"}          1998--2003      Retrospective              1306   Anemia at admission                                                     Inpatient mortality or discharge to hospice (combined end point)          Anemia was associated with outcome in patients with less severe stroke on subgroup analysis (aOR 4.17, 95% CI 1.47--11.90)
  Tanne et al[10](#jah31650-bib-0010){ref-type="ref"}        2001--2002      Prospective                859    Anemia at admission                                                     Mortality at 1 month and 1 year, functional outcome using Barthel Index   aOR for mortality at 1 month was 1.90 (95% CI 1.05--3.43) and at 1 year was 1.72 (95% CI 1.00--2.93)
  Wade et al[28](#jah31650-bib-0028){ref-type="ref"}         1977--1982      Post hoc analysis of RCT   1377   Hb \>15 vs ≥15 g/dL on study entry                                      Fatal and nonfatal strokes                                                No significant difference in Hb levels among those who died compared with survivors
  Zeng et al[22](#jah31650-bib-0022){ref-type="ref"}         2007--2008      Prospective                2513   Anemia on admission                                                     Mortality and dependency (mRS \>2) at 1, 3, 6, and 12 months              aOR for mortality in anemic versus nonanemic patients: 6 months 1.34 (95% CI 1.01--1.78), 1 year 1.33 (95% CI 1.00--1.75)

aOR indicates adjusted odds ratio; Hb, hemoglobin; HR, hazard ratio; ICH, intracerebral hemorrhage; mRS, modified Rankin Scale score; OR, odds ratio; Q, quintile; RCT, randomized controlled trial.

###### 

Characteristics Determining Study Validity

  Study                                                      Method of Stroke Diagnosis   Time of Mortality Measurement         Method of Mortality Measurement                             Confounders Adjusted for in Multivariate Logistic Regression                                                                                                                          Hb Cutoffs Used                                                           Stroke Types Considered
  ---------------------------------------------------------- ---------------------------- ------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------
  Bhatia et al[6](#jah31650-bib-0006){ref-type="ref"}        Imaging                      30 days                               Telephone, outpatient, or home interview                    ---                                                                                                                                                                                   ---                                                                       Both considered together
  Bussiere et al[23](#jah31650-bib-0023){ref-type="ref"}     Imaging                      30 days, 6 months, 1 year             Population registries                                       Age, sex, warfarin, INR, glucose, creatinine, blood pressure, IVH                                                                                                                     Quintiles, cutoffs; 100, 120, 140, 160 g/L; anemia defined as \<120 g/L   ICH only
  Chang et al[24](#jah31650-bib-0024){ref-type="ref"}        Imaging                      In‐hospital mortality                 Attending physician                                         Age, nadir Hb, ICH score, intubation                                                                                                                                                  Anemia (WHO definition)                                                   ICH only
  Czlonkowska et al[7](#jah31650-bib-0007){ref-type="ref"}   Imaging or autopsy           30 days                               ---                                                         Age, decreased consciousness, severity of weakness                                                                                                                                    ---                                                                       Both considered together
  Diedler et al[25](#jah31650-bib-0025){ref-type="ref"}      Imaging                      In‐hospital mortality                 Attending physician                                         Age, ICH volume, NIHSS, IVH, ICU stay, mechanical ventilation, RBC transfusion, mean Hb                                                                                               Anemia definition: \<12.1 g/L for women, \<13.1 g/L for men               ICH only
  Del Fabbro et al[16](#jah31650-bib-0016){ref-type="ref"}   ---                          In‐hospital, 1 year                   Telephone interview, population registries                  Age, GFR, comorbidities, functional status                                                                                                                                            Anemia (WHO definition)                                                   Both considered together
  Gray et al[26](#jah31650-bib-0026){ref-type="ref"}         Clinical evaluation          4 and 12 weeks                        ---                                                         Age, white cell count, hematocrit, Hb, urea                                                                                                                                           \>16 g/dL defined as elevated                                             Both considered together
  Hao et al[2](#jah31650-bib-0002){ref-type="ref"}           Imaging                      1 year                                ---                                                         Age, sex, comorbidities, smoking, alcohol, NIHSS, eGFR                                                                                                                                Anemia (WHO definition)                                                   AIS only
  Huang et al[17](#jah31650-bib-0017){ref-type="ref"}        Imaging                      3 years                               Outpatient interview                                        Age, comorbidities                                                                                                                                                                    Anemia (WHO definition)                                                   AIS only
  Kellert et al[8](#jah31650-bib-0008){ref-type="ref"}       Imaging                      3 months                              Telephone and outpatient interview                          Age, NIHSS, blood glucose, microcytic and hypochromic RBCs, leukocytosis, creatinine, CRP                                                                                             Anemia (WHO definition)                                                   AIS only
  Kumar et al[18](#jah31650-bib-0018){ref-type="ref"}        Imaging                      30 days                               Telephone interview, medical records, population registry   Age, sex, warfarin, ICH volume, IVH, glucose, WBC                                                                                                                                     Anemia (WHO definition)                                                   ICH only
  Kuramatsu et al[19](#jah31650-bib-0019){ref-type="ref"}    Imaging                      90 days and 1 year                    Telephone interview, mailed questionnaire                   NIHSS, GCS, ICH score, ICH volume, IVH, Graeb score, midline shift, Hb, hematocrit, mechanical ventilation, pneumonia                                                                 Anemia (WHO definition)                                                   ICH only
  Milionis et al[20](#jah31650-bib-0020){ref-type="ref"}     Imaging                      7 days, 3 months, 12 months           Medical records, death certificate, population registry     Age, sex, smoking, insurance, time to treatment, type of intervention, comorbidities, prior medication, BMI, blood pressure, heart rate, TOAST classification, metabolic parameters   Anemia (WHO definition)                                                   AIS only
  Nybo et al[21](#jah31650-bib-0021){ref-type="ref"}         Imaging                      6 months                              Population registry                                         Age, sex, comorbidities, Scandinavian stroke scale                                                                                                                                    Anemia (WHO definition)                                                   AIS only
  Park et al[9](#jah31650-bib-0009){ref-type="ref"}          ---                          3 months                              Telephone interview, chart review                           Age, sex, blood pressure, prestroke mRS, NIHSS, comorbidities, blood glucose, thrombolysis                                                                                            Prespecified quintiles                                                    AIS only
  Sharma et al[27](#jah31650-bib-0027){ref-type="ref"}       Imaging                      ---                                   ---                                                         Age, BMI, comorbidities, Hb, eGFR                                                                                                                                                     Hb \<13 g/dL                                                              AIS only
  Sico et al[1](#jah31650-bib-0001){ref-type="ref"}          Imaging                      In‐hospital                           ---                                                         Age, NIHSS                                                                                                                                                                            Hematocrit \<31%                                                          AIS only
  Tanne et al[10](#jah31650-bib-0010){ref-type="ref"}        Imaging                      Mortality at 1 year                   Population registry                                         Age, sex, stroke type, NIHSS, prior disability, comorbidities                                                                                                                         Anemia (WHO definition)                                                   Both considered separately
  Wade et al[28](#jah31650-bib-0028){ref-type="ref"}         Imaging                      ---                                   ---                                                         ---                                                                                                                                                                                   Cutoff at 15 g/dL                                                         AIS only
  Zeng et al[22](#jah31650-bib-0022){ref-type="ref"}         Imaging                      Discharge, 30 days, 3, 6, 12 months   Telephone interview                                         Age, sex, prestroke mRS, NIHSS, BMI, GCS, ICH volume, glucose, comorbidities, antithrombotic use, antihypoglycemic use, antihyperlipidemic use, family history, smoking, alcohol      Anemia (WHO definition)                                                   ICH only

AIS indicates arterial ischemic stroke; BMI, body mass index; CRP, C‐reactive protein; eGFR, estimated glomerular filtration rate; GCS, Glasgow Coma Scale; GFR, glomerular filtration rate; Hb, hemoglobin; ICH, intracerebral hemorrhage; ICU, intensive care unit; INR, International Normalized Ratio; IVH, intraventricular hematoma; mRS, modified Rankin Scale score; NIHSS, National Institutes of Health Stroke Scale; RBC, red blood cell; WBC, white blood cell; WHO, World Health Organization.

Validity Assessment {#jah31650-sec-0011}
-------------------

Different methods were used for ascertainment of stroke diagnosis. Imaging (computed tomography, magnetic resonance imaging, or both) was used in 17 studies,[1](#jah31650-bib-0001){ref-type="ref"}, [2](#jah31650-bib-0002){ref-type="ref"}, [6](#jah31650-bib-0006){ref-type="ref"}, [7](#jah31650-bib-0007){ref-type="ref"}, [8](#jah31650-bib-0008){ref-type="ref"}, [10](#jah31650-bib-0010){ref-type="ref"}, [17](#jah31650-bib-0017){ref-type="ref"}, [18](#jah31650-bib-0018){ref-type="ref"}, [19](#jah31650-bib-0019){ref-type="ref"}, [20](#jah31650-bib-0020){ref-type="ref"}, [21](#jah31650-bib-0021){ref-type="ref"}, [22](#jah31650-bib-0022){ref-type="ref"}, [23](#jah31650-bib-0023){ref-type="ref"}, [24](#jah31650-bib-0024){ref-type="ref"}, [25](#jah31650-bib-0025){ref-type="ref"}, [27](#jah31650-bib-0027){ref-type="ref"}, [28](#jah31650-bib-0028){ref-type="ref"} 1 study relied on clinical evaluation alone,[26](#jah31650-bib-0026){ref-type="ref"} and 2 did not state the method used.[9](#jah31650-bib-0009){ref-type="ref"}, [16](#jah31650-bib-0016){ref-type="ref"} The methods used to ascertain mortality also varied. Attending doctors confirmed in‐hospital mortality in 2 studies,[24](#jah31650-bib-0024){ref-type="ref"}, [25](#jah31650-bib-0025){ref-type="ref"} whereas death registry data were used in 4 studies.[10](#jah31650-bib-0010){ref-type="ref"}, [20](#jah31650-bib-0020){ref-type="ref"}, [21](#jah31650-bib-0021){ref-type="ref"}, [23](#jah31650-bib-0023){ref-type="ref"} Telephone interviews were used by 7 studies, typically in conjunction with other methods such as outpatient visit, home visit, mailed questionnaire, analysis of death registries, or review of medical records.[6](#jah31650-bib-0006){ref-type="ref"}, [8](#jah31650-bib-0008){ref-type="ref"}, [9](#jah31650-bib-0009){ref-type="ref"}, [16](#jah31650-bib-0016){ref-type="ref"}, [18](#jah31650-bib-0018){ref-type="ref"}, [19](#jah31650-bib-0019){ref-type="ref"}, [22](#jah31650-bib-0022){ref-type="ref"} One study used outpatient visits only,[17](#jah31650-bib-0017){ref-type="ref"} and the method used to establish mortality status was unclear in 6 studies.[1](#jah31650-bib-0001){ref-type="ref"}, [2](#jah31650-bib-0002){ref-type="ref"}, [7](#jah31650-bib-0007){ref-type="ref"}, [26](#jah31650-bib-0026){ref-type="ref"}, [27](#jah31650-bib-0027){ref-type="ref"}, [28](#jah31650-bib-0028){ref-type="ref"} Despite the variety of approaches taken to ascertain mortality, all seemed reliable.

Eleven studies used the World Health Organization definition of anemia as hemoglobin cutoffs,[2](#jah31650-bib-0002){ref-type="ref"}, [8](#jah31650-bib-0008){ref-type="ref"}, [10](#jah31650-bib-0010){ref-type="ref"}, [16](#jah31650-bib-0016){ref-type="ref"}, [17](#jah31650-bib-0017){ref-type="ref"}, [18](#jah31650-bib-0018){ref-type="ref"}, [19](#jah31650-bib-0019){ref-type="ref"}, [20](#jah31650-bib-0020){ref-type="ref"}, [21](#jah31650-bib-0021){ref-type="ref"}, [22](#jah31650-bib-0022){ref-type="ref"}, [24](#jah31650-bib-0024){ref-type="ref"} 7 used prespecified values,[1](#jah31650-bib-0001){ref-type="ref"}, [9](#jah31650-bib-0009){ref-type="ref"}, [23](#jah31650-bib-0023){ref-type="ref"}, [25](#jah31650-bib-0025){ref-type="ref"}, [26](#jah31650-bib-0026){ref-type="ref"}, [27](#jah31650-bib-0027){ref-type="ref"}, [28](#jah31650-bib-0028){ref-type="ref"} and 2 did not specify the values used.[6](#jah31650-bib-0006){ref-type="ref"}, [7](#jah31650-bib-0007){ref-type="ref"} By using prespecified thresholds in constructing categorical comparisons for anemia, it is possible that cut points have been drawn up that favor statistically significant findings. Eighteen studies adjusted for potential confounders[1](#jah31650-bib-0001){ref-type="ref"}, [2](#jah31650-bib-0002){ref-type="ref"}, [7](#jah31650-bib-0007){ref-type="ref"}, [8](#jah31650-bib-0008){ref-type="ref"}, [9](#jah31650-bib-0009){ref-type="ref"}, [10](#jah31650-bib-0010){ref-type="ref"}, [16](#jah31650-bib-0016){ref-type="ref"}, [17](#jah31650-bib-0017){ref-type="ref"}, [18](#jah31650-bib-0018){ref-type="ref"}, [19](#jah31650-bib-0019){ref-type="ref"}, [20](#jah31650-bib-0020){ref-type="ref"}, [21](#jah31650-bib-0021){ref-type="ref"}, [22](#jah31650-bib-0022){ref-type="ref"}, [23](#jah31650-bib-0023){ref-type="ref"}, [24](#jah31650-bib-0024){ref-type="ref"}, [25](#jah31650-bib-0025){ref-type="ref"}, [26](#jah31650-bib-0026){ref-type="ref"}, [27](#jah31650-bib-0027){ref-type="ref"}; however, there was great variation in terms of the variables adjusted for. These included age and National Institutes of Health Stroke Scale[1](#jah31650-bib-0001){ref-type="ref"} as well as age, sex, insurance status, smoking, time to treatment, type of intervention, prestroke medication, body mass index, blood pressure, heart rate, Trial of Org 10172 Acute Stroke Treatment criteria classification, metabolic parameters, and comorbidities.[20](#jah31650-bib-0020){ref-type="ref"} Consequently, many studies were liable to residual confounding (Table [6](#jah31650-tbl-0006){ref-type="table-wrap"}).

Meta‐analyses of pooled results showed that anemia is associated with an increased risk of mortality in ischemic stroke (pooled OR 1.97, 95% CI 1.57--2.47) (Figure [5](#jah31650-fig-0005){ref-type="fig"}).We also found a significant association for the evaluation of anemia and mortality in hemorrhagic stroke, albeit at a lower magnitude of association (OR 1.46, 95% 1.23--1.74) (Figure [6](#jah31650-fig-0006){ref-type="fig"}).The number of studies providing ORs for the relationship between elevated hemoglobin and stroke mortality was insufficient for a meta‐analysis to be conducted. Although available data suggest that elevated hemoglobin predicts short‐term mortality in ischemic stroke, findings are less consistent for hemorrhagic stroke (Table [7](#jah31650-tbl-0007){ref-type="table-wrap"}). The funnel plot depicting ORs for mortality in anemic ischemic stroke patients shows asymmetry (Figure [7](#jah31650-fig-0007){ref-type="fig"}), with an underrepresentation of studies on the left side that we would typically expect to consist of those reporting no significant harm in the relationship between anemia and stroke mortality. We encountered 5 such studies that reported no significant association in our systematic review that we could not incorporate into the meta‐analysis because ORs were not given, causing asymmetry in the funnel plot.

![Meta‐analysis of studies analyzing the impact of anemia at admission on mortality in ischemic stroke. IV indicates inverse variance.](JAH3-5-e003019-g005){#jah31650-fig-0005}

![Meta‐analysis of studies analyzing the impact of anemia at admission on mortality in hemorrhagic stroke. IV indicates inverse variance.](JAH3-5-e003019-g006){#jah31650-fig-0006}

###### 

Odds Ratios From Studies Evaluating Association Between Elevated Hemoglobin and Stroke Mortality

  Study                                                    Definition of Elevated Hemoglobin   Mortality Time Point   Number of Patients   Odds Ratio (95% CI)
  -------------------------------------------------------- ----------------------------------- ---------------------- -------------------- ---------------------
  Ischemic stroke                                                                                                                          
  Park et al[9](#jah31650-bib-0009){ref-type="ref"}        Prespecified quintile               3 months               2681                 1.99 (1.02--3.91)
  Current study, men                                       \>17 g/dL                           In‐patient             3298                 1.85 (1.03--3.32)
  1 month                                                                                      1.79 (1.00--3.20)                           
  3 months                                                                                     1.86 (1.08--3.18)                           
  6 months                                                                                     1.46 (0.86--2.48)                           
  1 year                                                                                       1.50 (0.91--2.47)                           
  Current study, women                                     \>15.5 g/dL                         In‐patient             3653                 1.30 (0.87--1.94)
  1 month                                                                                      1.49 (1.01--2.21)                           
  3 months                                                                                     1.19 (0.81--1.75)                           
  6 months                                                                                     1.12 (0.78--1.62)                           
  1 year                                                                                       1.04 (0.73--1.48)                           
  Hemorrhagic stroke                                                                                                                       
  Bussiere et al[23](#jah31650-bib-0023){ref-type="ref"}   \>16 g/dL                           1 year                 2406                 1.00 (0.74--1.33)
  Current study, men                                       \>17 g/dL                           In‐patient                                  3.20 (1.19--9.17)
  1 month                                                                                      2.90 (1.08--7.75)                           
  3 months                                                                                     2.08 (0.75--5.78)                           
  6 months                                                                                     1.56 (0.56--4.40)                           
  1 year                                                   513                                 1.56 (0.56--4.35)                           
  Current study, women                                     \>15.5 g/dL                         In‐patient             549                  2.76 (1.16--6.56)
  1 month                                                                                      2.11 (0.92--4.82)                           
  3 months                                                                                     2.08 (0.91--4.77)                           
  6 months                                                                                     2.99 (1.29--6.90)                           
  1 year                                                                                       2.63 (1.14--6.05)                           

![Funnel plot of odds ratios from studies analyzing the impact of anemia at admission on mortality in ischemic stroke.](JAH3-5-e003019-g007){#jah31650-fig-0007}

Discussion {#jah31650-sec-0012}
==========

Our study examined the association between anemia and hemoglobin levels and mortality in acute stroke in a large unselected stroke patient population and sought to quantify this association using systematic review and meta‐analysis. At 24.5%, prevalence of anemia was high in the cohort analyzed in the current study. Low hemoglobin levels were associated with older age, increased stroke severity, higher prestroke disability, and the increased comorbidity burden. This suggested that outcomes were mediated by the impact of confounders; however, we found anemia to be independently associated with mortality subsequent to making the appropriate adjustments. A systematic review and meta‐analysis of the literature confirmed our findings. In addition, we found elevated hemoglobin to be associated with poorer outcomes in acute stroke, suggesting a U‐shaped relationship between hemoglobin levels and stroke mortality.

The literature has described several pathological mechanisms that can plausibly explain the independent association between anemia and increased mortality risk in stroke. First, by lowering the oxygen‐carrying capacity of blood, anemia may intensify ischemia and thus hypoxia within the penumbral lesions in patients with ischemic stroke.[29](#jah31650-bib-0029){ref-type="ref"}, [30](#jah31650-bib-0030){ref-type="ref"} Second, anemia can compromise cerebrovascular autoregulation, leading to fluctuations in cerebral perfusion; this alters the delivery of oxygen to the brain,[31](#jah31650-bib-0031){ref-type="ref"}, [32](#jah31650-bib-0032){ref-type="ref"} thereby exacerbating damage caused by ischemia or hemorrhage. Third, augmentation of cerebral blood flow can create turbulence, which can trigger the migration of an existing thrombus and lead to a thromboembolism.[33](#jah31650-bib-0033){ref-type="ref"} Fourth, anemia may lead to hyperdynamic circulation, which has been shown to modulate the expression of adhesion molecules on vascular endothelial cells by upregulating their production. This may trigger an inflammatory response that leads to thrombus formation in a process similar to atherosclerosis.[34](#jah31650-bib-0034){ref-type="ref"}, [35](#jah31650-bib-0035){ref-type="ref"} Fifth, anemia may worsen outcomes in stroke because of its relationship with inflammatory mediators; it can upregulate the production of inducible nitric oxide synthase and CXC chemokine receptor 4,[36](#jah31650-bib-0036){ref-type="ref"} both of which have been associated with brain damage during ischemia.[37](#jah31650-bib-0037){ref-type="ref"}, [38](#jah31650-bib-0038){ref-type="ref"}

In addition to the pathophysiological mechanisms described, there is also a plausible clinical explanation for the excess mortality risk in stroke patients with anemia. It may be the case that anemic patients were less likely to be prescribed antithrombotics because of the increased risk of bleeding. This was suggested by a finding shown in Table [4](#jah31650-tbl-0004){ref-type="table-wrap"} in which fewer anemic women who had a positive vascular indication were on prior antithrombotics compared with those without anemia. This finding potentially supports the well‐documented differential management of cardiovascular risk factors between sexes. The reverse trends were observed for those without vascular indications, supporting previous observations that inappropriate prescribing may be more prevalent for women.

The association between anemia and mortality suggests that interventions may improve outcomes. Although previous studies have shown that packed red blood cell transfusions reduce mortality at 30‐days in anemic patients with myocardial infarction,[39](#jah31650-bib-0039){ref-type="ref"} a recent systematic review and meta‐analysis found that blood transfusion after percutaneous coronary intervention is associated with adverse outcomes,[40](#jah31650-bib-0040){ref-type="ref"} casting doubt on the potential benefits of packed red blood cell transfusions in anemic stroke patients. Observational studies reporting the association between mortality and transfusion in anemic patients with hemorrhagic stroke have had varied results, with one finding a reduction in mortality[41](#jah31650-bib-0041){ref-type="ref"} and another finding no change.[18](#jah31650-bib-0018){ref-type="ref"} To the knowledge of the authors, no studies assessing the impact of packed red blood cell transfusion on anemic ischemic stroke patients have been conducted. Because of the paucity of evidence, guidelines have been unable to specify hemoglobin targets or optimal management options.[11](#jah31650-bib-0011){ref-type="ref"} A randomized controlled trial is required to gauge the impact of transfusions and to establish optimum hemoglobin ranges in patients with acute stroke.

Our study has a number of strengths. The stroke cases were prospectively identified, and the cohort had almost complete follow‐up using validated methods. Because a large sample population was used, it was possible to conduct a rigorous analysis by sex and stroke type, enabling us to provide new insights. We were also able to control for a diverse array of confounders, thereby mitigating the effects of residual confounding. The meta‐analysis included patients from a wide array of countries, increasing the generalizability of our findings. The inclusion of a large number of participants in the meta‐analysis provided sufficient statistical power to obtain results for both stroke subtypes. Finally, all studies included in the meta‐analysis were of high methodological quality.

This study has some limitations. The small sample number of patients with hemorrhagic stroke may have contributed to the nonsignificant *P* values. Some of the models used did not fit the data well. Hosmer--Lemeshow tests were significant for ischemic stroke in men at 3 and 6 months and 1 year (Table [2](#jah31650-tbl-0002){ref-type="table-wrap"}). Although this result does not alter the associations found, it indicates that for this subgroup, there may be other factors or interactions that might help better predict mortality outcome at these time points. It is possible that we were not able to control for unknown factors. In this registry‐based study, we were not able to fully adjust for treatment effect (eg, blood transfusion, use of iron supplements and erythropoietin‐stimulating agents). Nonetheless, transfusion for mild to moderate anemia in stroke is not a routine practice, and the likelihood of such confounding is minimal. We were unable to consider the duration of anemia or to assess the impact of abnormal hemoglobin levels subsequent to a stroke; therefore, the independent association between anemia and excess mortality in stroke cannot be described as a causal relationship. The studies in the meta‐analysis had high heterogeneity for ischemic stroke (I^2^\>50%). Finally, the possibility of underrepresentation of studies that reported no significant harm in the relationship between anemia and stroke mortality raises the issue of selective reporting. Consequently, our meta‐analysis may have overinflated estimates of the association between anemia and excess mortality risk.

In conclusion, we showed that a significant proportion of stroke patients have anemia at the time of stroke onset and that this is associated with increased mortality up to 1 year. The optimal treatment option in this patient group is unclear. Studies are required to examine the clinical and cost‐effectiveness of interventions in this patient population in an acute stroke setting.
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